News

Neurofibromatosis Type 1 (NF1) Drug Development Gains Momentum Amid Growing Need For Safer, More Effective Therapies
DataM Intelligence | competitive Intelligence NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibito ...
Nasdaq24d
Pasithea Therapeutics Initiates Phase 1/1b Clinical Trial for PAS-004 in Adult Patients with Neurofibromatosis Type 1
The trial aims to provide insights on both plexiform and cutaneous neurofibromas and is supported by an anticipated Australian R&D Tax Incentive refund of up to 48.5% of eligible costs.
Yahoo Finance24d
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is ...
manilatimes24d
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. The first active clinical trial site is the Royal North Shore Hospital in Sydney, Australia, which is ...
Seeking Alpha24d
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site
Exploratory objectives include assessing the effects of PAS-004 on cutaneous neurofibromas. Pasithea has selected Novotech (Australia) Pty Limited as its clinical research organization (CRO ...
Yahoo Finance23d
Pasithea to commence Phase I/Ib trial of neurofibromatosis type 1 therapy
and assessing preliminary efficacy on target plexiform neurofibroma volume and cutaneous neurofibromas. Part A of the trial will enrol up to 24 subjects who will be given one of four planned PAS ...